Methotrexate is widely administered with mercaptopurine, a prodrug requiring activation into thioguanine nucleotides (TGN) to exert antileukemic effects. In vitro, methotrexate enhances TGN formation, but in vivo, such enhancement has yet to be demonstrated. We investigated whether TGN concentrations were related to methotrexate concentrations in children with acute lymphoblastic leukemia who received a weekly intravenous methotrexate ( 
Introduction
The combination of methotrexate and mercaptopurine forms the cornerstone of continuation therapy for childhood acute lymphoblastic leukemia (ALL). The pharmacologic rationale for the combination is based in part on biochemical and pharmacokinetic effects of methotrexate on mercaptopurine metabolism. Mercaptopurine (the analogue of hypoxanthine) is a prodrug requiring intracellular activation by a multienzymatic process involving hypoxanthine phosphoribosyltransferase (HPRT) to exert antileukemic effects. HPRT converts mercaptopurine into thioinosine monophosphate, which is subsequently metabolized into active cytotoxic thioguanine nucleotides (TGNs) . 1 This process is in competition with direct inactivation of mercaptopurine by xanthine oxidase or by polymorphic thiopurine methyltransferase. 2 The formation of TGNs is an important component of the antileukemic effect of mercaptopurine. 1 Erythrocyte TGNs have been positively correlated with long-term event-free survival 3 and to hematopoietic toxicity following thiopurine therapy. 4 By inhibition of glycinamide ribonucleotide formyltransferase, aminoimidazole carboxamide ribonucleotide formyltransferase, and dihydrofolate reductase, methotrexate and its long-chain polyglutamate metabolites inhibit de novo purine synthesis. 5 A consequence of inhibiting de novo purine synthesis is an increase in concentrations of phosphoribosyl pyrophosphate (PRPP), a co-substrate for HPRT-catalyzed for- mation of thioinosine monophosphate. In vitro, the increase in PRPP levels by methotrexate is sequence-, time-and dosedependent, 6 although it is not clear that a higher dose of methotrexate produces higher concentrations of TGN. In vivo, methotrexate also inhibits xanthine oxidase, resulting in decreased first pass metabolism and increased mercaptopurine bioavailability. 7 However, it has not been demonstrated whether an increase of plasma mercaptopurine concentrations by methotrexate is associated with enhancement of intracellular TGN concentrations. Moreover, the optimal dose of methotrexate to enhance TGN accumulation is unknown, and enhanced TGN formation by methotrexate has yet to be demonstrated during continuation therapy of ALL.
Because we measured chronic systemic exposure to both methotrexate and mercaptopurine active metabolites in a recent study that was heavily dependent upon these agents, 8 we had a unique opportunity to evaluate whether TGNs were higher among those with higher methotrexate polyglutamate concentrations.
Methods
Children with ALL were treated on St Jude Children's Research Hospital Total XII trial, after approval by our institutional review board and appropriate informed consent. 8 Erythrocyte TGNs and methotrexate polyglutamate concentrations (MTX-PG) were scheduled to be measured at weeks 7, 31, 55, 82, 106 and 120 of continuation therapy. Erythrocyte TGNs and MTXPGs were measured by HPLC as described. 9, 10 At each scheduled sampling, a research nurse reviewed with the patient and guardian the dosing history of mercaptopurine and methotrexate for the prior 6 weeks. For inclusion in this analysis, the following criteria had to be met: (1) the patient was scheduled to receive mercaptopurine (75 mg/m 2 /day) with intravenous methotrexate (40 mg/m 2 / week) for at least 3 weeks preceding blood sampling; (2) the research nurse subjectively assessed that the patient was likely compliant with the treatment; (3) patients had wild-type TPMT activity or genotype; 4 and (4) erythrocyte TGN concentrations were measured concomitantly with erythrocyte MTX-PG concentrations. Only four observations were excluded, meeting all other criteria but whose mercaptopurine dose was different from 75 mg/m 2 /day. These criteria allowed us to assess whether MTXPGs correlated with TGNs by minimizing variability in both measures due to alterations in dosing due to polymorphism in TPMT (Figure 1 ).
Results and discussion
A total of 141 measurements determined in 87 patients (average of 1.6 measurements per patient) met the criteria described above. A total of 12 measurements were available Algorithm for inclusion of thioguanine nucleotides (TGN) and methotrexate polyglutamates (MTXPG) for these analyses. Of 709 erythrocyte TGN measurements, 141 met the criteria for this analysis.
at week 7, 37 measurements were available at week 31, 36 at week 55, 31 at week 82, eight at week 106 and 17 at week 120. In the 141 available samples, total MTX-PG concentrations ranged from 0.30 to 76.3 pmol/10 9 cells (median 27 pmol/10 9 cells) and long-chain polyglutamate concentrations (MTX-PG [5] [6] [7] 11 Among the 87 patients, only 12 had more than two measurements of RBC TGNs and MTX-PG during continuation therapy (median of three determinations per patient, range 3-5). Among these 12 patients, the intrapatient coefficient of variation ranged from 2 to 65% (median 18%) for TGNs, from 19% to 92% (median 44%) for total MTXPGs, and from 13% to 117% for MTXPG [5] [6] [7] concentrations (median 42%).
Average (per-patient) erythrocyte TGNs correlated positively with average (per-patient) erythrocyte MTX-PG 5-7 concentrations (Spearman rank test: r = 0.33 P = 0.002; n = 87; Figure 2 panel a) , but not significantly with total average (per-patient) erythrocyte methotrexate polyglutamate concentrations (MTX-PG [1] [2] [3] [4] [5] [6] [7] : r = 0.14; P = 0.18; n = 87). Average (perpatient) MTXPG [1] [2] [3] [4] concentrations correlated positively with TGNs concentrations but did not reach significance (r = 0.20; P = 0.06; n = 87). In addition, at weeks 31, 55 and 82 (each group containing more than 30 measurements with only one measurement per patient), higher MTX-PG 5-7 concentrations remained correlated with TGNs ( Figure 2 panel b-d) .
Long-chain MTX-PGs are known to be retained intracellularly more avidly than methotrexate and short-chain MTX-PG, and they more potently inhibit de novo purine synthesis. 12 Thus, the positive relationship between TGN levels and longchain MTX-PG concentrations we observed is consistent with their inhibition of de novo purine synthesis and increased PRPP formation.
It is important to note that erythrocytes lose the ability to synthesize purines de novo during their maturation process 13 whereas the ability to synthesize PRPP is preserved.
14 Previous reports have demonstrated that erythrocyte methotrexate polyglutamates arise from incorporation of the drug into red cell precursors, 15, 16 and that erythrocyte TGN concentrations reach steady state after weeks of oral mercaptopurine. 17 Therefore, it is conceivable that an inhibition of de novo purine synthesis by methotrexate polyglutamates during early stages of erythroblast development (colony-forming erythroid, pro-erythroblast or reticulocyte cells) may enhance PRPP formation and hence, TGN formation. However, it is also possible that the mature circulating erythrocytes may have high PRPP concentrations secondary to de novo purine synthesis inhibition during maturation, thereby enhancing TGN formation. In addition, the inhibition of xanthine oxidase by methotrexate leading to an increase in mercaptopurine bioavailability may contribute to higher TGN formation. 7 Numerous clinical studies have reported large interpatient variability in erythrocyte TGNs during continuation therapy of ALL. 3, 8, [18] [19] [20] Determinants of this variability include differences in mercaptopurine absorption, thiopurine methyltransferase activity, and patient compliance to treatment. In addition to these factors, variations in methotrexate polyglutamate concentrations could partly explain interpatient variability in intracellular TGNs. Therefore, differences in methotrexate uptake or efflux, or alternatively in methotrexate's polyglutamate anabolism and/or catabolism, might indirectly affect formation of TGNs.
A previous report did not observe a relationship between total MTX-PG concentrations and TGNs. 19 The apparent discrepancy with our results could be due to the fact that we focussed on a subset of patients who had all received the same mercaptopurine and methotrexate dose and all of whom were wild-type for TPMT. Also, we did not find a significant associ- ation between the total MTXPG concentrations and TGN levels, only an association of long-chain MTXPGs and TGNs, consistent with the more potent effects of long-chain rather than short-chain MTX-PGs on DNPS.
The Total XII trial was somewhat unusual relative to current ALL trials, in that low-dose methotrexate and oral mercaptopurine were given essentially continuously. Moreover, methotrexate was administered parenterally at a dose of 40 mg/m 2 , whereas other protocols usually include oral methotrexate at a dosage of 20 mg/m 2 . 3, 18, 19, 21 The erythrocyte TGNs we observed were generally higher than those of other trials that included lower methotrexate doses. 3 Hence, conceivably, the higher concentration of TGNs we observed may have been related to the higher methotrexate dose administered.
In conclusion, these data support the notion that methotrexate may enhance the formation of active thioguanine nucleotides during continuation therapy for acute lymphoblastic leukemia.
